HomeCompareTRXDW vs GBDC

TRXDW vs GBDC: Dividend Comparison 2026

TRXDW yields 1333.33% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRXDW wins by $241528679.83M in total portfolio value
10 years
TRXDW
TRXDW
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full TRXDW calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — TRXDW vs GBDC

📍 TRXDW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRXDWGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRXDW + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRXDW pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRXDW
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, TRXDW beats the other by $178,904,467,130,671.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRXDW + GBDC for your $10,000?

TRXDW: 50%GBDC: 50%
100% GBDC50/50100% TRXDW
Portfolio after 10yr
$120764360.69M
Annual income
$105,237,938,230,834.98/yr
Blended yield
87.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

TRXDW
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Altman Z
-42.6
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRXDW buys
0
GBDC buys
0
No recent congressional trades found for TRXDW or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRXDWGBDC
Forward yield1333.33%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$241528700.61M$20.78M
Annual income after 10y$210,475,860,072,406.56$16,389,263.41
Total dividends collected$239239876.27M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: TRXDW vs GBDC ($10,000, DRIP)

YearTRXDW PortfolioTRXDW Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$144,033$133,333.33$12,490$1,790.28+$131.5KTRXDW
2$1,948,924$1,794,807.89$16,522$3,157.73+$1.93MTRXDW
3$24,782,219$22,696,870.86$23,578$5,898.68+$24.76MTRXDW
4$296,245,945$269,728,970.81$37,115$11,886.75+$296.21MTRXDW
5$3,330,378,004$3,013,394,842.54$66,136$26,423.57+$3330.31MTRXDW
6$35,223,684,321$31,660,179,856.69$137,257$66,491.44+$35223.55MTRXDW
7$350,636,384,108$312,947,041,885.16$341,734$194,868.54+$350636.04MTRXDW
8$3,286,630,500,315$2,911,449,569,318.85$1,050,788$685,133.02+$3286629.45MTRXDW
9$29,021,346,295,663$25,504,651,660,325.88$4,099,314$2,974,971.01+$29021342.20MTRXDW
10$241,528,700,608,766$210,475,860,072,406.56$20,775,530$16,389,263.41+$241528679.83MTRXDW

TRXDW vs GBDC: Complete Analysis 2026

TRXDWStock

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Full TRXDW Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this TRXDW vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRXDW vs SCHDTRXDW vs JEPITRXDW vs OTRXDW vs KOTRXDW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.